|By Marketwired .||
|May 27, 2014 08:30 AM EDT|
MILTON, ONTARIO -- (Marketwired) -- 05/27/14 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQB:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., announced that effective with the opening of the market today, the Company's common stock is trading under the symbol "TRX" on the TSX Venture Exchange ("TSX-V").
Rob Harris, President and CEO for Tribute commented, "This is a very significant event for us today, being Tribute's first day trading on the TSX-V. As a Canadian specialty pharmaceutical company, primarily focused on the Canadian marketplace with offices in both Milton, Ontario and London, Ontario, the TSX.-V listing provides Tribute with greater access to the Canadian capital markets and Canadian investors."
About Tribute Pharmaceuticals Canada Inc.
Tribute is a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S. markets.
Tribute markets Cambia® (diclofenac potassium for oral solution), Bezalip® SR (bezafibrate), Soriatane® (acitretin), NeoVisc® (1.0% sodium hyaluronate solution) Uracyst® (sodium chondroitin sulfate solution 2%) and Collatamp G® in the Canadian market. Additionally, NeoVisc® and Uracyst® are commercially available and are sold globally through various international partnerships. Tribute also has the exclusive U.S. rights to develop and commercialize Bezalip® SR in the U.S. and has the exclusive right to sell bilastine a product licensed from Faes Farma for the treatment of Allergic Rhinitis and Chronic Idiopathic Urticaria (hives) in Canada. The exclusive license is inclusive of prescription and non-prescription rights for bilastine, as well as adult and pediatric presentations in Canada. This product is subject to receiving Canadian regulatory approval.
Tribute Pharmaceuticals' Forward-Looking Statement
This press release contains certain forward-looking statements about Tribute as defined in the Private Securities Litigation Reform Act of 1995, which statements can be identified by the use of forward-looking terminology, such as "may", "will", "expect", "intend", "anticipate", "estimate", "predict", "plan" or "continue" or the negative thereof or other variations thereon or comparable terminology referring to future events or results. Forward-looking statements, by their nature, are subject to risks and uncertainties, Tribute actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, any of which could cause actual results to vary materially from current results or anticipated future results. See Tribute reports filed with the Canadian Securities Regulatory Authorities and the U.S. Securities and Exchange Commission from time to time for cautionary statements identifying important factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause actual results to differ materially from results referred to in forward-looking statements. Tribute assumes no obligation to update the information contained in this press release to update forward-looking statements to reflect changed assumptions, the occurrence of anticipated events or changes in future operating results, financial condition or business over time.
Bezalip® SR and Soriatane® are registered trademarks and under license from Actavis Group PTC ehf. Cambia® is a registered trademark and under license from Depomed, Inc. Collatamp G® is a registered trademark and under license EUSA Pharma (Europe) Limited.
For further information on Tribute visit the Company's website: http://www.tributepharma.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Jul. 24, 2016 10:00 PM EDT Reads: 1,940
Jul. 24, 2016 09:45 PM EDT Reads: 2,116
Jul. 24, 2016 09:45 PM EDT Reads: 1,902
Jul. 24, 2016 09:45 PM EDT Reads: 1,624
Jul. 24, 2016 09:00 PM EDT Reads: 1,463
Jul. 24, 2016 09:00 PM EDT Reads: 2,457
Jul. 24, 2016 07:45 PM EDT Reads: 1,845
Jul. 24, 2016 07:30 PM EDT Reads: 1,706
Jul. 24, 2016 07:30 PM EDT Reads: 1,687
Jul. 24, 2016 07:30 PM EDT Reads: 2,048
Jul. 24, 2016 07:15 PM EDT Reads: 1,854
Jul. 24, 2016 07:00 PM EDT Reads: 1,926
Jul. 24, 2016 06:45 PM EDT Reads: 2,033
Jul. 24, 2016 06:45 PM EDT Reads: 1,756
Jul. 24, 2016 06:15 PM EDT Reads: 1,376